All In Biotech

Drug Trial Radar · NCT05710224

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)

A Phase 2, Randomized, Double-Blind, Multicenter, Safety and Immunogenicity Clinical Bridging Study to Compare V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,364 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,364

Actual

Start

Feb 15, 2023

Primary completion

Jan 22, 2024

Study completion Dec 12, 2024

Sponsor

Lead sponsor
Butantan InstituteGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Merck Sharp & Dohme LLC
First posted
Feb 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study was to demonstrate that V181 is safe and well tolerated and elicits an immune response that is non-inferior to that of Butantan - DV at Day 28 post-vaccination in adults 18 to 50 years of age in Brazil. The primary hypothesis was that V181 is non-inferior to Butantan - DV for each of the 4 dengue serotypes based on geometric mean titers (GMTs) and seroconversion rates at Day 28 post-vaccination.

Conditions

  • Dengue

Interventions

  • V181Biological

    0.5 mL SC dose of V181

  • Butantan - DVBiological

    0.5 mL SC dose of Butantan - DV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dengue Virus (DENV)-Neutralizing Antibody Titers as Measured by Virus Reduction Neutralization Test (VRNT)Time frame: Day 28 post-vaccination
  2. Percentage of Participants Who Seroconverted, as Measured by VRNTTime frame: Day 28 post-vaccination
  3. Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)Time frame: Up to 28 days post-vaccination

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Tacchini (Site 0006)

    Bento Gonçalves, Rio Grande do Sul, Brazil

  • Fundação Universidade de Caxias do Sul (FUCS) - Instituto de Pesquisas em Saúde (IPS) (Site 0017)

    Caxias do Sul, Rio Grande do Sul, Brazil

  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia (Site 0005)

    Ijuí, Rio Grande do Sul, Brazil

  • Hospital São Vicente de Paulo-Education and Research Management (Site 0007)

    Passo Fundo, Rio Grande do Sul, Brazil

  • Instituto Méderi de Pesquisa e Saúde (0020)

    Passo Fundo, Rio Grande do Sul, Brazil

  • Hospital Escola da Universidade Federal de Pelotas (Site 0009)

    Pelotas, Rio Grande do Sul, Brazil

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre-Centro de Pesquisa em Infectologia (Site # 003)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Núcleo de Pesquisa Clínica do Rio Grande do Sul (Site 0011)

    Porto Alegre, Rio Grande do Sul, Brazil

  • LMK Serviços Médicos S/S-Reumacenter (Site 0004)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Moinhos de Vento - Centro de Pesquisa Clínica (Site0021)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital São Lucas da PUCRS-Centro de Pesquisa Clínica HSL-PUCRS (Site 0015)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Universidade Federal de Santa Maria (UFSM) - Hospital Univer-Unidade de Pesquisa Clínica-UPC (Site 0001)

    Santa Maria, Rio Grande do Sul, Brazil

  • Clínica Supera (Site 0019)

    Chapecó, Santa Catarina, Brazil

  • Criciuma (Site 0008)

    Passo Fundo, Santa Catarina, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.